Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl Inc (VRX.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 10,758,416
  • Shares Outstanding, K 349,299
  • Annual Sales, $ 8,724 M
  • Annual Income, $ 2,404 M
  • 36-Month Beta -1.49
  • Price/Sales 0.96
  • Price/Cash Flow 4.64
  • Price/Book 1.85
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -2.64
  • Most Recent Earnings -7.68 on 03/31/18
  • Next Earnings Date 08/14/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 1.000 on 11/10/10
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate 1.04
  • Number of Estimates 6
  • High Estimate 1.19
  • Low Estimate 0.91
  • Prior Year 1.41
  • Growth Rate Est. (year over year) -26.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.80 +3.36%
on 07/06/18
35.73 -13.80%
on 06/15/18
-4.09 (-11.72%)
since 06/13/18
3-Month
21.10 +45.97%
on 04/16/18
36.02 -14.49%
on 06/13/18
+9.18 (+42.46%)
since 04/13/18
52-Week
14.01 +119.84%
on 11/02/17
36.02 -14.49%
on 06/13/18
+8.78 (+39.87%)
since 07/13/17

Most Recent Stories

More News
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into an incremental term loan facility amendment (the "Incremental Amendment") to its...

VRX.TO : 30.80 (-3.33%)
Ophthalmology Devices Market Report 2018 Focuses on Production, Consumption, Revenue (Million USD), Market Share and Growth Rate: Radiant Insights, Inc.: Radiant Insights, Inc.

The Global Ophthalmology Devices Market is projected to develop at a substantial CAGR for the duration of the prediction. The growing number of ocular complaints are the development features of ophthalmology...

VRX.TO : 30.80 (-3.33%)
JNJ : 133.00 (-10.04%)
AGN : 148.23 (-1.74%)
ELXMF : 0.4913 (+4.53%)
IRIX : 4.15 (-2.58%)
NVS : 87.39 (-1.14%)
QUTEF : 7.8000 (unch)
CZMWF : 79.7500 (+5.14%)
SHAREHOLDER ALERT: Former Shareholders of Synergetics USA Investigating Claim for Breach of Contract Relating to Contingent Value Rights

A committee of former shareholders of Synergetics USA, Inc. ("Synergetics"), led by Kurt Gampp, who are current holders of Contingent Value Rights (CVRs) under the September 1, 2015 Contingent Value Rights...

VRX.TO : 30.80 (-3.33%)
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins

LAVAL, Quebec , June 12, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
OUT : 19.35 (-1.38%)
Valeant Announces Pricing Of Private Offering Of Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary,...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary,...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans

LAVAL, Quebec , May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference

Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant To Seek Refinancing of its Existing Credit Agreement

LAVAL, Quebec , May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 32.69
1st Resistance Point 31.74
Last Price 30.80
1st Support Level 30.30
2nd Support Level 29.81

See More

52-Week High 36.02
Last Price 30.80
Fibonacci 61.8% 27.61
Fibonacci 50% 25.01
Fibonacci 38.2% 22.42
52-Week Low 14.01

See More

Business Summary

Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar